Israeli scientists: Coronavirus vaccine to be tested on humans by June 1
[INTRODUCTION BY ADINA KUTNICKI: Since the outbreak of the CHINESE VIRUS, civilized people – regardless of their race, religion, or political persuasion – should applaud, and be heartened by, the front-line input by tiny (and continually maligned) Israel. But don’t hold your breath. Be that as it may, consider the following contributions as (more than) proof positive:
The Israeli Pharmaceutical Company Teva has made an incredible donation to the US’ efforts to fight the coronavirus in the form of 6 million doses of chloroquine.
MIGAL and IIBR are both testing potential COVID-19 vaccinations on mammals
A team of Israeli researchers says that they are days away from completing the production of the active component of a coronavirus vaccine that could be tested on humans as early as June 1.
“We are in the final stages and within a few days we will hold the proteins – the active component of the vaccine,” Dr. Chen Katz, group leader of MIGAL’s biotechnology group, told The Jerusalem Post.
In late February, MIGAL (The Galilee Research Institute) committed to completing production of its vaccine within three weeks and having it on the market in 90 days. Katz said they were slightly delayed because it took longer than expected to receive the genetic construct that they ordered from China due to the airways being closed and it having to be rerouted.
As a reminder, for the past four years, researchers at MIGAL have been developing a vaccine against infectious bronchitis virus (IBV), which causes a bronchial disease affecting poultry. The effectiveness of the vaccine has been proven in preclinical trials carried out at the Veterinary Institute.
Our basic concept was to develop the technology and not specifically a vaccine for this kind or that kind of virus,” said Katz. “The scientific framework for the vaccine is based on a new protein expression vector, which forms and secretes a chimeric soluble protein that delivers the viral antigen into mucosal tissues by self-activated endocytosis, causing the body to form antibodies against the virus.”
Endocytosis is a cellular process in which substances are brought into a cell by surrounding the material with cell membrane, forming a vesicle containing the ingested material.
In preclinical trials, the team demonstrated that the oral vaccination induces high levels of specific anti-IBV antibodies, Katz said.
